Cargando…

Comparative effectiveness of natalizumab versus ocrelizumab in multiple sclerosis: a real-world propensity score–matched study

BACKGROUND: For treatment of relapsing-remitting multiple sclerosis (RRMS), a broad range of disease-modifying therapies (DMT) is available. However, few comparative effectiveness studies between different drugs have been performed. OBJECTIVES: This study aimed to compare the efficacy and treatment...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pape, Katrin, Rolfes, Leoni, Steffen, Falk, Muthuraman, Muthuraman, Korsen, Melanie, Meuth, Sven G., Zipp, Frauke, Bittner, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9772974/ https://www.ncbi.nlm.nih.gov/pubmed/36568489 http://dx.doi.org/10.1177/17562864221142924

Ejemplares similares

Ocrelizumab initiation in patients with MS: A multicenter observational study
por: Ellwardt, Erik, et al.
Publicado: (2020)

Ocrelizumab Extended Interval Dosing in Multiple Sclerosis in Times of COVID-19
por: Rolfes, Leoni, et al.
Publicado: (2021)

Serum neurofilament levels reflect outer retinal layer changes in multiple sclerosis
por: Seitz, Caspar B., et al.
Publicado: (2021)

Supplementary medication in multiple sclerosis: Real-world experience and potential interference with neurofilament light chain measurement
por: Pape, Katrin, et al.
Publicado: (2020)

Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers
por: Brummer, Tobias, et al.
Publicado: (2022)

Neurological update: treatment escalation in multiple sclerosis patients refractory to fingolimod—potentials and risks of subsequent highly active agents
por: Korsen, Melanie, et al.
Publicado: (2022)

NfL predicts relapse-free progression in a longitudinal multiple sclerosis cohort study: Serum NfL predicts relapse-free progression
por: Uphaus, Timo, et al.
Publicado: (2021)

Continuous reorganization of cortical information flow in multiple sclerosis: A longitudinal fMRI effective connectivity study
por: Fleischer, Vinzenz, et al.
Publicado: (2020)

Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab
por: Pfeuffer, Steffen, et al.
Publicado: (2023)

Longitudinal cortical network reorganization in early relapsing–remitting multiple sclerosis
por: Fleischer, Vinzenz, et al.
Publicado: (2019)

Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS
por: Engel, Sinah, et al.
Publicado: (2019)

Network alterations underlying anxiety symptoms in early multiple sclerosis
por: Ellwardt, Erik, et al.
Publicado: (2022)

Skin Reactions in Patients With Multiple Sclerosis Receiving Cladribine Treatment
por: Rolfes, Leoni, et al.
Publicado: (2021)

Ocrelizumab versus fingolimod after natalizumab cessation in multiple sclerosis: an observational study
por: Bigaut, Kévin, et al.
Publicado: (2022)

Treatment approaches to patients with multiple sclerosis and coexisting autoimmune disorders
por: Brummer, Tobias, et al.
Publicado: (2021)

Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients
por: van Lierop, ZYGJ, et al.
Publicado: (2021)

Impact of Dietary Intervention on Serum Neurofilament Light Chain in Multiple Sclerosis
por: Bock, Markus, et al.
Publicado: (2021)

Linking Microstructural Integrity and Motor Cortex Excitability in Multiple Sclerosis
por: Radetz, Angela, et al.
Publicado: (2021)

Covarying patterns of white matter lesions and cortical atrophy predict progression in early MS
por: Muthuraman, Muthuraman, et al.
Publicado: (2020)

Structural Brain Network Characteristics Can Differentiate CIS from Early RRMS
por: Muthuraman, Muthuraman, et al.
Publicado: (2016)

Selective Brain Network and Cellular Responses Upon Dimethyl Fumarate Immunomodulation in Multiple Sclerosis
por: Ciolac, Dumitru, et al.
Publicado: (2019)

Immune response to SARS-CoV-2 vaccination in relation to peripheral immune cell profiles among patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Alemtuzumab/natalizumab/ocrelizumab: COVID-19: 3 case reports
Publicado: (2021)

Stable multiple sclerosis patients on anti-CD20 therapy should go on extended interval dosing—“Yes”
por: Rolfes, Leoni, et al.
Publicado: (2021)

MOG encephalomyelitis: distinct clinical, MRI and CSF features in patients with longitudinal extensive transverse myelitis as first clinical presentation
por: Loos, Julia, et al.
Publicado: (2020)

Vaccine-based clinical protection against SARS-CoV-2 infection and the humoral immune response: A 1-year follow-up study of patients with multiple sclerosis receiving ocrelizumab
por: Räuber, Saskia, et al.
Publicado: (2022)

Clinical and economic evaluations of natalizumab, rituximab, and ocrelizumab for the management of relapsing-remitting multiple sclerosis in Saudi Arabia
por: Alharbi, Mansour A., et al.
Publicado: (2023)

Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab
por: Toorop, Alyssa A., et al.
Publicado: (2020)

Evaluation of Age-Dependent Immune Signatures in Patients With Multiple Sclerosis
por: Eschborn, Melanie, et al.
Publicado: (2021)

Immune Response to Seasonal Influenza Vaccination in Multiple Sclerosis Patients Receiving Cladribine
por: Rolfes, Leoni, et al.
Publicado: (2023)

Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses
por: Pfeuffer, Steffen, et al.
Publicado: (2022)

Gray matter integrity predicts white matter network reorganization in multiple sclerosis
por: Radetz, Angela, et al.
Publicado: (2019)

Neuronal ICAM-5 Plays a Neuroprotective Role in Progressive Neurodegeneration
por: Birkner, Katharina, et al.
Publicado: (2019)

Gray matter network reorganization in multiple sclerosis from 7‐Tesla and 3‐Tesla MRI data
por: Gonzalez‐Escamilla, Gabriel, et al.
Publicado: (2020)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Rolfes, Leoni, et al.
Publicado: (2020)

Failed, Interrupted, or Inconclusive Trials on Neuroprotective and Neuroregenerative Treatment Strategies in Multiple Sclerosis: Update 2015–2020
por: Huntemann, Niklas, et al.
Publicado: (2021)

Sex-specific signatures of intrinsic hippocampal networks and regional integrity underlying cognitive status in multiple sclerosis
por: Ciolac, Dumitru, et al.
Publicado: (2021)

Teriflunomide treatment is associated with optic nerve recovery in early multiple sclerosis
por: Pfeuffer, Steffen, et al.
Publicado: (2021)

COVID-19 Vaccine Response in People with Multiple Sclerosis Treated with Dimethyl Fumarate, Diroximel Fumarate, Natalizumab, Ocrelizumab, or Interferon Beta Therapy
por: Jaber, Aliya, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_990nve8k5n44bnr90vfmf5l3rp